浙江醫藥(600216.SH):上半年淨利潤同比預增90.28%-128.33%
格隆匯7月14日丨浙江醫藥(600216.SH)公佈2025年半年度業績預告,預計2025年半年度實現歸屬於上市公司股東的淨利潤爲60,000.00萬元-72,000.00萬元,同比增加90.28%-128.33%。公司預計2025年半年度歸屬於上市公司股東的扣除非經常性損益的淨利潤爲59,000.00萬元-70,800.00萬元,同比增加86.27%-123.53%。
2025年上半年,在激烈的市場競爭與複雜的經濟環境下,公司穩抓安全生產和產品質量,全面落實各項生產經營重點工作。在報告期內,公司生命營養品板塊主導產品市場需求與銷售價格較上年同期有所增長,導致銷售收入較上年同期相應增長,爲公司業績上升提供了主要驅動力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.